On the contrary, the anti-platelet effects of CXCR7-agonist are counteracted by IP-receptor antagonist and pharmacological inhibitors of the AC-cAMP-PKA pathway in both healthy donors and CAD patients ex vivo (Figure 3) [76]. The gene discussed is ACKR3; the disease is coronary artery disorder.